Navigation Links
Infectious Disease Research Institute Receives Grant from the Bill & Melinda Gates Foundation for Adjuvant Access and Development

SEATTLE, Dec. 4 /PRNewswire/ -- The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit scientific research institute, announced today that it has received a $29,947,850 five year grant from the Bill & Melinda Gates Foundation. The grant will be used to provide adjuvants (essential components for many vaccines) for priority malaria vaccine candidates. Advances arising from this project are likely also to facilitate development of vaccines against other neglected diseases.

Adjuvants are vaccine components that, when appropriately formulated and combined with an antigen, direct the immune system to give an effective response while boosting the potency and longevity of the specific immune responses. Most adjuvants are owned by large pharmaceutical companies and not easily accessible to researchers developing vaccines for neglected diseases. IDRI seeks to provide the public sector with safe, effective, low-cost adjuvants through component testing and licensing, product improvement, development of adjuvant-antigen formulations, and the creation of an adjuvant library.

With this grant, IDRI will focus on adjuvants for malaria vaccines. Because malaria parasites have a complex life cycle, creating an effective vaccine is a major scientific challenge. Worldwide, every year between 350 million and 500 million people are infected with malaria and more than 1 million die from this preventable disease. To accelerate the fight against malaria, IDRI will obtain access to adjuvants with proven clinical potential in malaria vaccines and will develop next-generation adjuvant formulations for malaria vaccine candidates.

"This grant enables IDRI to help advance the development of malaria vaccines," said Dr. Steven Reed, Founder and Head of IDRI's Research and Development Program. "We are honored that the Gates Foundation has provided this opportunity and look forward to working with researchers in the field of malaria."

IDRI, in partnership with the World Health Organization in Geneva, will work closely with the PATH Malaria Vaccine Initiative and other agencies and investigators to select priority malaria antigens for preliminary development and testing of these adjuvant formulations.

About IDRI

IDRI is a non-profit organization committed to developing technologies to treat "neglected" diseases that place a significant burden on those living in the developing world. IDRI achieves its mission by working closely with industry, universities, and hospitals in developed and developing countries, government and private funding agencies, and the World Health Organization. For more information, go to

SOURCE The Infectious Disease Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
2. Infectious diseases experts applaud bill against bad bugs
3. MultiVu Video Feed: Parents of Kids With Infectious Diseases Sounds Alarm About the Dangers of Pertussis With "Silence the Sounds of Pertussis" Campaign
4. Einstein scientists treat cancer as an infectious disease -- with promising results
5. Northwestern exposing most deadly infectious diseases in 3-D
6. Southern Research Institute Names Vladimir Yamshchikov Director of Infectious Disease Research Department in Birmingham
7. Study shows suppressing herpes virus may reduce infectiousness of HIV
8. Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director
9. Smoking may strongly increase long-term risk of eye disease
10. Pot bellies linked to early signs of cardiovascular disease
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
Post Your Comments:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: